EXCESSIVE MURAL CALCIUM OVERLOAD - A PREDOMINANT CAUSAL FACTOR IN THE DEVELOPMENT OF STENOSING CORONARY PLAQUES IN HUMANS

被引:35
作者
FLECKENSTEIN, A
FREY, M
THIMM, F
FLECKENSTEINGRUN, G
机构
[1] Study Group for Calcium Antagonism Physiological Institute of the University of Freiburg, Freiburg, D-7800
关键词
ATHEROGENESIS; CALCIUM OVERLOAD; CORONARY PLAQUE TISSUE; SEVERITY OF PLAQUES; CHOLESTEROL ACCUMULATION; ANTIARTERIOSCLEROTIC EFFECTS OF CALCIUM ANTAGONISTS;
D O I
10.1007/BF02018309
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Healthy human coronary artery walls contain, over their entire lifetime, more free and total cholesterol than calcium. However, as soon as arteriosclerotic alterations set in, the calcium content increases. Thus in coronary fatty streaks (arteriosclerotic plaques of WHO stage I), calcium was increased 13 times, in stage II plaques 25 times, and in fully developed stage III plaques 80 times above normal on average. The most dramatic calcium incrustation was found in coronary stage III plaques that had produced massive fatal coronary infarction. Here, the proportion of calcium salts (particularly hydroxyapatite) may amount to almost 50% of dry weight. Thus the most excessive accumulation of calcium seems to be correlated with the highest fatality. In contrast, there is no correlation between mural coronary free or total cholesterol content, and plaque severity. Accordingly, stenosing coronary stage III plaques contain less cholesterol than do fatty streaks. Moreover, in coronary stage III plaques the proportion of free cholesterol was 1.37%, and of total cholesterol only 2.34% of the whole mass, certainly not enough for directly causing coronary occlusion. Thus the calcium-rich plaques of human coronary arteries considerably differ from the well-known cholesterol-rich plaques (stage I and II) of human aortae. Our findings justify a new prophylactic approach with suitable calcium antagonists to interfere with deleterious calcium uptake in coronary plaque development.
引用
收藏
页码:1005 / 1014
页数:10
相关论文
共 31 条
[1]  
Abell L.L., Levy B.B., Brodie B.B., Kendall F.E., A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity, J. Biol Chem., 195, pp. 357-366, (1952)
[2]  
McGill H.C., Characterization of atherosclerotic lesions as they pertain to noninvasive, techniques, Atherosclerosis reviews, vol. 10: Noninvasive methods in atherosclerosis research, pp. 1-5, (1983)
[3]  
Small D.M., Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. George Lyman Duff Memorial Lecture, Arterioslcerosis, 8, pp. 103-129, (1988)
[4]  
Anitschkow N., Chalatow S., Über experimentelle Cholesterinsteatose und ihre Bedeutung für die Entstehung einiger pathologischer Prozesse, Zentralbl f Allgemeine Pathol u Anat, 14, pp. 1-9, (1913)
[5]  
Katase A., Experimentelle Verkalkung am gesunden Tiere, Beiträge Path Anat und Allg Path, 57, pp. 516-550, (1913)
[6]  
Herzenberg H., Studien über die Wirkungsweise des bestrahlten Ergosterins (Vigantol) und die Beziehungen der von ihm gesetzten Veränderungen zur Arteriosklerose, Beitr Path Anat, 82, pp. 27-56, (1929)
[7]  
Hass G.M., Trueheart R.E., Hemmens A., Experimental arteriosclerosis due to hypervitaminosis D, Am J Pathol, 37, pp. 521-539, (1960)
[8]  
Eisenstein R., Zeruolis L., Vitamin-D-induced aortic calcification, Arch Pathol, 77, pp. 27-35, (1964)
[9]  
Yogamundi Moon J., Factors affecting arterial calcification associated with atherosclerosis. A review, Atherosclerosis, 16, pp. 119-126, (1972)
[10]  
Fleckenstein A., Kammermeier H., Doring H.J., Et al., Zum Wirkungsmechanismus neuatiger Koronardilatatoren mit gleichzeitig Sauerstoff-einsparenden Myokard-Effekten, Prenylamin und Iproveratril, Z.f. Kreislaufforsch, 56, pp. 716-744, (1967)